USPTO Examiner KIM YUNSOO - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18774608COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024January 2025Allow610YesNo
18774646COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024April 2025Allow920YesNo
18774629COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024March 2025Allow820YesNo
18444471COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOFFebruary 2024November 2024Allow911YesNo
18439344Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial ApplicationsFebruary 2024November 2024Allow911YesNo
18439336Method for Making Nano-sized Chitosan/VS2 NanocompositesFebruary 2024October 2024Allow820NoNo
18507324Nano-sized Chitosan/VS2 nanocomposite like flowers for Potential Pharmaceutical ApplicationsNovember 2023July 2024Allow921YesNo
18341437COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJune 2023May 2024Allow1011YesNo
18324097Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use ThereofMay 2023March 2024Allow1021NoNo
18305919Production of Biosimilar Ustekinumab in CHO CellsApril 2023June 2024Allow1320YesNo
18300064PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USEApril 2023January 2024Allow911YesNo
18161036PROTEIN-TYPE NANOPARTICLES, PREPARATION METHODS, AND APPLICATION THEREOFJanuary 2023December 2023Allow1121NoNo
18086031HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONSDecember 2022February 2024Allow1411YesNo
18002248COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USEDecember 2022December 2024Allow2421YesYes
18054101COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITINGNovember 2022November 2024Abandon2421NoNo
17863587METHOD FOR PURIFYING IMMUNOGLOBULIN SOLUTIONSJuly 2022June 2025Abandon3501NoNo
17831645EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSINGJune 2022June 2025Abandon3601NoNo
17832463METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDESJune 2022June 2025Allow3620YesNo
17731671FORMULATION CONTAINING TLR AGONIST AND METHODS OF USEApril 2022May 2025Allow3721YesNo
17732224Thermostable Vaccine Compositions and Methods of Preparing The SameApril 2022June 2025Allow3811YesNo
17726741HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)April 2022March 2025Abandon3510NoNo
17675488USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSISFebruary 2022February 2025Abandon3601NoNo
17584286PROTEIN FORMULATIONS AND METHODS OF MAKING SAMEJanuary 2022February 2025Abandon3601NoNo
17572350Production of Biosimilar Ustekinumab In CHO CellsJanuary 2022March 2025Abandon3811NoNo
17552392METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSESDecember 2021May 2025Abandon4111NoNo
17542632VISCOSITY REDUCTION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONSDecember 2021December 2024Allow3621NoNo
17457456USE OF AMINO ACIDS AS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTSDecember 2021May 2024Abandon2911NoNo
17534218NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULESNovember 2021August 2024Abandon3301NoNo
17455713FORMULATIONS OF MONOCLONAL ANTIBODIESNovember 2021February 2025Abandon3930NoNo
17519141HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATIONNovember 2021October 2024Allow3521NoNo
17514957PROCESS FOR PREPARING AN IMMUNOGLOBULIN PREPARATIONOctober 2021September 2024Allow3420NoNo
17503759Novel Formulations Which Stabilize Low Dose Antibody CompositionsOctober 2021April 2025Abandon4121NoNo
17470270METHODS AND COMPOSITIONS FOR TARGETING T-CELL CANCERSSeptember 2021June 2024Abandon3301NoNo
17437634PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-LINGO-1 ANTIBODIESSeptember 2021May 2025Abandon4401NoNo
17460979IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAMEAugust 2021March 2024Allow3010NoNo
17393888METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINESAugust 2021January 2025Allow4231YesNo
17391663NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENTAugust 2021January 2025Abandon4221NoNo
17386385COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONSJuly 2021November 2023Allow2820NoNo
17378025STABLE LIQUID ANTIBODY FORMULATIONJuly 2021February 2024Abandon3110NoNo
17350781LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSEJune 2021August 2024Abandon3820NoNo
17332521EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSINGMay 2021November 2024Abandon4221NoNo
17320693STABILIZED ANTIBODY COMPOSITIONSMay 2021January 2024Allow3220NoNo
17316585Thermostable Vaccine Compositions and Methods of Preparing sameMay 2021May 2024Allow3611YesNo
17291194ANTI-PTK7 IMMUNE CELL CANCER THERAPYMay 2021March 2025Abandon4611NoNo
17246288METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNSApril 2021March 2024Allow3420YesNo
17233008Composition Comprising an AntibodyApril 2021July 2024Allow3920YesNo
17225887Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) AntibodiesApril 2021April 2024Allow3620NoNo
17224900FORMULATIONS OF MONOCLONAL ANTIBODIESApril 2021October 2024Abandon4321NoNo
17211399AQUEOUS PHARMACEUTICAL FORMULATIONSMarch 2021December 2023Abandon3301NoNo
17211459METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCEMarch 2021January 2024Abandon3410NoNo
17200552CONJUGATE VACCINE TARGETING A DISEASE-CAUSING BIOLOGICAL PROTEINMarch 2021March 2024Allow3611YesNo
17197603COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOFMarch 2021November 2024Abandon4421NoNo
17191589IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOFMarch 2021September 2024Abandon4321NoNo
17179223NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAPFebruary 2021July 2024Allow4121YesNo
17177022HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONSFebruary 2021November 2023Abandon3301NoNo
17175162EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONSFebruary 2021August 2023Allow3061YesNo
17170667COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASEFebruary 2021November 2024Allow4531YesNo
17165704PROTEIN-NANOPARTICLE CONJUGATE PURIFICATION METHODSFebruary 2021October 2023Allow3220NoNo
17155432STABLE ANTIBODY FORMULATIONJanuary 2021February 2025Allow4950YesNo
17152054COMPOSITIONS COMPRISING AN ANTI-C5 ANTIBODYJanuary 2021October 2023Abandon3320NoNo
17260334FCRN ANTIBODY COMPOSITIONSJanuary 2021April 2025Allow5121YesNo
17128736METHOD FOR TREATMENT OF A LEUKOCYTE RELATED DISEASE BY DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES USING TARGETED LIPID PARTICLESDecember 2020April 2024Allow4021YesNo
17254508METHODS OF PRODUCING ANTI-C5 ANTIBODIESDecember 2020April 2025Allow5120NoNo
17116587AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMABDecember 2020November 2023Abandon3510NoNo
17106105Engineered BiofilmsNovember 2020March 2025Abandon5221NoNo
17105358COMPOSITIONS AND METHODS FOR PRODUCING A COMPOSITIONNovember 2020February 2024Allow3921YesNo
17101966ANTI-PDL1 ANTIBODY FORMULATIONSNovember 2020October 2023Abandon3501NoNo
17101063Liquid Protein Formulations Containing Viscosity-Lowering AgentsNovember 2020June 2024Abandon4321NoNo
17091553ANTI-ABETA THERAPEUTIC VACCINESNovember 2020March 2024Allow4021YesNo
17052696STABLE HYBRID FC FUSION G-CSF FORMULATIONNovember 2020December 2024Allow5030NoNo
17073618Liquid Protein Formulations Containing 4-Ethyl-4-Methylmorpholinium Methylcarbonate (EMMC)October 2020October 2023Allow3621NoNo
17047462QUALITATIVE ANALYSIS OF PROTEINSOctober 2020June 2025Allow5621YesYes
17067058Liquid Protein Formulations Containing Cyclic Adenosine Monophosphate (cAMP) or Adenosine Triphosphate (ATP)October 2020July 2023Allow3311NoNo
17040702FULL FLOW-THROUGH PROCESS FOR PURIFYING RECOMBINANT PROTEINSSeptember 2020April 2025Allow5541YesNo
17017465PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOFSeptember 2020February 2024Allow4121YesNo
17011014EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONSSeptember 2020August 2024Abandon4811NoNo
16977142METHODS FOR PURIFYING RECOMBINANT POLYPEPTIDESSeptember 2020April 2024Abandon4310NoNo
16943378HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONSJuly 2020December 2023Abandon4011NoNo
16954868LIQUID FORMULATIONS OF ANTI-CD200 ANTIBODIESJune 2020July 2024Allow4941YesNo
16772407METHODS OF INDUCING IMMUNE TOLERANCE AND REDUCING ANTI-DRUG ANTIBODY RESPONSEJune 2020February 2025Abandon5641NoNo
16891249MULTISPECIFIC PROTEINSJune 2020October 2023Abandon4011NoNo
16767994LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETINMay 2020August 2023Allow3921YesNo
16765786PHARMACEUTICAL COMPOSITIONSMay 2020August 2023Allow3921YesNo
16876839ANTI-CD3 ANTIBODY FORMULATIONSMay 2020March 2025Abandon5841YesNo
16876812Methods for Targeted Delivery of Agents to Degraded Elastic FibersMay 2020January 2024Allow4421YesNo
15931062METHODS FOR PURIFYING ANTIBODIESMay 2020January 2025Allow5630YesNo
16763193AFLIBERCEPT FORMULATIONS CONTAINING A LYSINE SALT AS TONICIFYING AGENT AND USES THEREOFMay 2020August 2024Allow5231YesNo
16859750DOSAGE REGIMENS FOR AND COMPOSITIONS INCLUDING ANTI-RSV ANTIBODIESApril 2020February 2024Allow4631YesNo
16858349TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGENApril 2020December 2023Abandon4351NoYes
16852196Peptide Conjugated ParticlesApril 2020July 2023Allow3921YesNo
16756409Pharmaceutical Composition of Humanized Monoclonal Anti-PD-L1 AntibodyApril 2020August 2024Allow5222YesNo
16839249Method of Administration of an Anti-IFN-alpha/-omega AntibodyApril 2020September 2024Allow5341YesNo
16815635NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSEMarch 2020July 2023Allow4021NoNo
16640422PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS CONTAINING ANTI-ALPHA(V)BETA(6) ANTIBODIESFebruary 2020October 2023Abandon4421NoNo
16638339BRAF-SPECIFIC TCRS AND USES THEREOFFebruary 2020April 2025Allow6021YesNo
16778128OPTIMIZED METHOD FOR ANTIBODY CAPTURING BY MIXED MODE CHROMATOGRAPHYJanuary 2020August 2024Allow5420YesNo
16632851POLYMERIC NANOPARTICLES FOR ENHANCED CANCER IMMUNOTHERAPYJanuary 2020November 2023Allow4541YesNo
16487990STABILIZED ANTIBODY SOLUTIONSJanuary 2020November 2023Abandon5131NoNo
16715580PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODYDecember 2019December 2023Allow4831YesNo
16697999STABILIZED AQUEOUS ANTIBODY COMPOSITIONSNovember 2019September 2023Allow4631NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, YUNSOO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
3
(42.9%)
Examiner Reversed
4
(57.1%)
Reversal Percentile
81.7%
Higher than average

What This Means

With a 57.1% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
46
Allowed After Appeal Filing
15
(32.6%)
Not Allowed After Appeal Filing
31
(67.4%)
Filing Benefit Percentile
47.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KIM, YUNSOO - Prosecution Strategy Guide

Executive Summary

Examiner KIM, YUNSOO works in Art Unit 1641 and has examined 195 patent applications in our dataset. With an allowance rate of 75.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner KIM, YUNSOO's allowance rate of 75.9% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by KIM, YUNSOO receive 2.85 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KIM, YUNSOO is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +43.3% benefit to allowance rate for applications examined by KIM, YUNSOO. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 61.7% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.